Gyre Therapeutics, Inc.
Balance Sheet
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $43.3M | $37.5M | $49.2M | $40.4M | $36.5M | $15.0M | $11.8M | $15.9M |
| Accounts Receivable | $27.8M | $22.8M | $31.1M | $25.9M | $24.6M | $20.2M | $19.6M | — |
| Inventory | $11.4M | $11.4M | $10.2M | — | $8.9M | $7.9M | $6.3M | $6.4M |
| Total Current Assets | $122.1M | $91.7M | $149.4M | $98.6M | $91.3M | $68.4M | $64.8M | $54.8M |
| Property, Plant & Equipment | $27.3M | $23.6M | $27.5M | $23.6M | $23.4M | $23.5M | $23.9M | $24.4M |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | $4.5M | $4.6M | $4.7M | $4.8M | $5.0M | $5.1M | $273.0K | $184.0K |
| Total Assets | $199.3M | $162.0M | $219.8M | $159.4M | $152.6M | $129.8M | $125.4M | $125.2M |
| Liabilities | ||||||||
| Accounts Payable | $1.2M | $265.0K | $1.3M | $556.0K | $71.0K | $122.0K | $108.0K | $303.0K |
| Total Current Liabilities | $28.7M | $19.8M | $23.8M | $15.9M | $16.9M | $19.0M | $19.5M | $14.7M |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Total Liabilities | $34.3M | $25.0M | $31.4M | $22.0M | $23.2M | $25.5M | $27.0M | $26.8M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-138.0M | $-77.7M | $-112.6M | $-66.7M | $-70.3M | $-70.8M | $-73.5M | $-73.4M |
| Total Stockholders' Equity | $107.9M | $101.3M | $62.5M | $101.9M | $92.0M | $68.1M | $63.3M | $63.2M |